Glaukos
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Visit website
LLY Eli Lilly and Company |
$1415.67 | -1.12% |
JNJ Johnson & Johnson |
$279.92 | -0.93% |
ABBV AbbVie |
$293.22 | -0.45% |
MRK Merck & Co. |
$144.11 | -0.24% |
UNH UnitedHealth Group Incorp… |
$396.28 | -3.82% |